NCT03222856 Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes Status COMPLETED Phase PHASE2
NCT03221634 Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668) Status WITHDRAWN Phase PHASE2
NCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Status COMPLETED Phase PHASE3
NCT03220477 Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03219450 A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. Status RECRUITING Phase PHASE1
NCT03217071 Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT03213041 Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Status COMPLETED Phase PHASE2
NCT03212651 Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab Status COMPLETED Phase PHASE2
NCT03211416 Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT03211117 Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer Status COMPLETED Phase PHASE2
NCT03210662 Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Status COMPLETED Phase PHASE2
NCT03204188 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Status COMPLETED Phase PHASE2
NCT03197636 Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients Status COMPLETED Phase N/A
NCT03197506 Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03197467 Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT03197389 Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. Status COMPLETED Phase EARLY_PHASE1
NCT03196232 Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer Status COMPLETED Phase PHASE2
NCT03192059 Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer Status COMPLETED Phase PHASE2
NCT03191981 Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma Status WITHDRAWN Phase PHASE1/PHASE2
NCT03189719 First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) Status COMPLETED Phase PHASE3